A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

NCT01060904 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Disease, Hodgkin

Interventions

DRUG: brentuximab vedotin
DRUG: doxorubicin
DRUG: vinblastine
DRUG: dacarbazine
DRUG: bleomycin
DRUG: brentuximab vedotin

Sponsor

Seagen Inc.

Collaborators

[object Object]